Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3790-3796

  Perdigão Olivieri, Bianca ^a   Cotta de Almeida, Vinícius ^a,b   Araújo Jorge, Tania ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CD4 ANTIGEN; CD8 ANTIGEN; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOREGULATION; INFECTION RESISTANCE; LYMPHOID ORGAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; SPLEEN CELL; SPLENOMEGALY; T LYMPHOCYTE; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; IMMUNOLOGY; RECURRENT DISEASE; SPLEEN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; MALE; MICE; NITROIMIDAZOLES; RECURRENCE; SPLEEN; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0036896423     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3790-3796.2002     Document Type: Article

References (43)

1. Abrahamsohn, I. A., and R. L. Coffman. 1996. Trypanosoma cruzi: IL-10, TNF, IFN-γ and IL-12 regulate innate and acquired immunity to infection. Exp. Parasitol. 84:231-244.
2. Andrade, S. G., and R. M. Figueira. 1977. Estudo experimental sobre a ação terapêutica da droga Ro 7-1051 na infecção por diferentes cepas do Trypanosoma cruzi. Rev. Inst. Med. Trop. São Paulo 19:335-341.
3. Andrade, S. G., L. A. R. Freitas, S. Peyrol, A. R. Pimentel, and M. Sardigursky. 1991. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bull. W. H. O. 69:191-197.
4. Andrade, S. G., S. Stocker-Guerret, A. S. Pimentel, and J. A. Grimaud. 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem. Inst. Oswaldo Cruz 86:187-200.
5. Araújo-Jorge, T. C., E. P. Sampaio, W. De Souza, and M. N. L. Meirelles. 1989. Trypanosoma cruzi: The effect of variations in experimental conditions on the levels of macrophage infection in vitro. Parasitol. Res. 75:257-263.
6. Bahia-Oliveira, L. M., J. A. Gomes, J. R. Cançado, T. C. Ferrari, E. S. Lemos, Z. M. Luz, M. C. Moreira, G. Gazzinelli, and R. Corrêa-Oliveira. 2000. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis. 182:634-638.
7. Bahia-Oliveira, L. M. G., J. A. S. Gomes, E. S. Lemos, L. M. P. Luz, M. E. S. Pereira, R. L. Coffman, J. C. P. Dias, J. R. Cançado, M. O. C. Rocha, M. C. V. Moreira, G. Gazzinelli, and R. Corrêa-Oliveira. 1998. IFN-γ in human Chagas' disease: Protection or pathology? Braz. J. Med. Biol. Res. 31:127-131.
8. Brener, Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop São Paulo 4:386-396.
9. Cabeza Meckert, P., J. G. Chambo, and R. P. Laguens. 1988. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response. Antimicrob. Agents Chemother. 32:241-245.
10. Coura, J. R., and S. L. De Castro. 2002. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97:3-24.
11. De Castro, S. L. 1993. The challenge of Chagas' disease chemotherapy: An update of drugs assayed against Trypanosoma cruzi. Acta Trop. 53:83-98.
12. De Gaspari, E. N., E. S. Umezawa, B. Zingales, A. M. Stolf, W Colli, and I. A. Abrahmsohn. 1990. Trypanosoma cruzi: Serum antibody reactivity to the parasite antigens in susceptible and resistant mice. Mem. Inst. Oswaldo Cruz 85:261-270.
13. Dos Reis, G. A. 1997. Cell-mediated immunity in experimental Trypanosoma cruzi-infection. Parasitol. Today 13:335-342.
14. Dutra, W. O., Z. M. P. Luz, J. R. Cançado, M. E. Pereira, R. M. Brigido-Nunes, L. M. C. Galvão D. G. Colley, Z. Brener, G. Gazzinelli, and J. F. Carvalho-Parra. 1996. Influence of parasite presence on the immunological profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol. 18:579-585.
15. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
16. Galvão, L., R. Nunes, J. R. Cançado, Z. Brener, and A. Krettli. 1993. Lytic antibodies titer as a means of assessing cure after treatment of Chagas' disease: A 10 year follow-up study. Trans. R. Soc. Trop. Med. Hyg. 87:220-223.
17. Gonçalves-da-Costa, S. C., P. H. Lagrange, B. Hurtrel, I. Keer, and A. Alencar. 1984. Role of T lymphocytes in the resistance and immunopathology of experimental Chagas'disease. I. Histopathological studies. Ann. Inst. Pasteur Immunol. 135:317-332.
18. Henriques-Pons, A., G. M. Oliveira, M. M. Paiva, A. F. S. Correa, M. M. Batista, R. C. Bisaggio, C.-C. Liu, V. Cotta-de-Almeida, C. M. L. M. Coutinho, P. M. Persechini, and T. C. Araújo-Jorge. 2002. Evidence of a perforin-mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infection. Int. J. Exp. Pathol. 83:67-79.
19. Krettli, A., J. R. Cançado, and Z. Brener. 1982. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 76:334-340.
20. Laguens, R. P., M. I. Argel, J. Chambo, R. Storino, and P. M. Cabeza-Meckert. 1994. Presence of antiheart and antiskeletal muscle glycolipid autoantibodies in the sera of patients with chagasic cardiopathy. Can. J. Cardiol. 10:769-776.
21. + T-cell death by the T-cell receptor CD3 pathway and not by the CD69 or Ly-6 activation pathway. Infect. Immun. 64:1559-1564.
22. + T cell death by apoptosis in experimental Chagas' disease. J. Immunol. 154:744-752.
23. Michailowsky, V., S. M. F. Murta, L. Carvalho-Oliveira, M. E. Pereira, L. R. P. Ferreira, Z. Brener, A. J. Romanha, and R. T. Gazzinelli. 1998. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:2549-2556.
24. Minoprio, P., A. Coutinho, M. Joskowicz, M. R. D'Imperio-Lima, and H. Eisen. 1986. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. II. Cytotoxic T lymphocytes. Scand. J. Immunol. 24:669-679.
25. Minoprio, P., H. Eisen, L. Forni, M. R., D'Imperio Lima, M. Joskowicz, and A. Coutinho. 1986. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. I. Quantitation of both T- and B-cell responses. Scand. J. Immunol. 24:661-668.
26. Minoprio, P., S. Itohara, C. Heusser, S. Tonegawa, and A. Coutinho. 1989. Immunobiology of murine Trypanosoma cruzi infection: the predominance of parasite-nonspecific responses and the activation of TCRI T cells. Immunol. Rev. 112:183-207.
27. Oehen, S., and K. Brduscha-Riem. 1998. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161:5338-5346.
28. Piaggio, E., E. Roggero, M. Pitashny, J. Wietzerbin, O. A. Botasso, and S. S. Revelli. 1987. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitol. Res. 87:539-547.
29. Plata, F., F. Garcia-Pons, and J. Wietzerbin. 1987. Immune resistance to Trypanosoma cruzi: Synergy of specific antibodies and recombinant interferon gamma in vivo. Ann. Inst. Pasteur Immunol. 138:397-415.
30. Reed, S. G. 1998. Immunology of Trypanosoma cruzi infections. Chem. Immunol. 70:124-143.
31. Richle, R. 1973. Chemotherapy of experimental acute Chagas' disease in mice: beneficial effect of Ro 7-1051 on parasitaemia and tissue parasitism. Prog. Med. 101:282.
32. Savino, W., M. C. Leite-de-Moraes, M. Hontebeyrie-Joskowicz, F. Leboulenger, and M. Dardenne. 1989. Studies on the thymus in Chagas'disease. I. Changes in the thymic microenvironment in mice acutely infected with Trypanosoma cruzi. Eur. J. Immunol. 19:1727-1733.
33. Schmid, I., C. H. Uittenbogaart, B. Keld, and J. V. Giorgi. 1994. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods 170:145-157.
34. Segura, E. L., A. Molina de Raspi, and M. A. Basombrio. 1994. Reversibility of muscle and heart lesions in chronic Trypanosoma cruzi infected mice after late trypanomicidal treatment. Mem. Inst. Oswaldo Cruz 89:213-216.
35. Silva, J. S., P. J. Morrissey, K. H. Grabstein, K. M. Mohler, D. Anderson, and S. G. Reed. 1992. Interleukin 10 and interferon γ regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 175:169-174.
36. Silva, L. H. P., and V. Nussenszweig. 1953. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin. Biol. 20: 191-208.
37. Souza, A. P., B. P. Olivieri, S. L. De Castro, and T. C. Araújo-Jorge. 2000. Enzymatic markers of heart lesion in mice infected with Trypanosoma cruzi and submitted to benznidazole chemotherapy. Parasitol. Res. 86:800-808.
38. Tarleton, R. L. 1995. The role of T cells in Trypanosoma cruzi infection. Parasitol. Today 1:7-9.
39. Tarleton, R. L., B. H. Koller, A. Latour, and M. Postan. 1992. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356:338-340.
40. Urbina, J. 1999. Chemotherapy of Chagas' disease: The how and the why. J. Mol. Med. 77:332-338.
41. Viotti, R., C. Vigliano, H. Armenti, and E. Segura. 1994. Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am. Heart J. 127:151-162.
42. World Health Organization. 1997. Prospects for the elimination of some TDR diseases. Wkly. Epidemiol. Rec. 23-35.
43. Zhang, L., and R. L. Tarleton. 1999. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J. Infect. Dis. 180:480-486.